Suppr超能文献

Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.

作者信息

Strijbis Emm, Koch M W, de Jong B A

机构信息

Department of Neurology, MS Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.

出版信息

Mult Scler. 2023 Aug;29(9):1066-1067. doi: 10.1177/13524585231182708. Epub 2023 Jul 25.

Abstract
摘要

相似文献

2
Quality of life should be the primary outcome for disease-modifying therapy trials in MS: Commentary.
Mult Scler. 2023 Aug;29(9):1068-1069. doi: 10.1177/13524585231182702. Epub 2023 Jul 25.
3
Quality of life should be the primary outcome for disease-modifying therapy trials in MS-Yes.
Mult Scler. 2023 Aug;29(9):1064-1065. doi: 10.1177/13524585231182705. Epub 2023 Jul 25.
7
Teriflunomide for multiple sclerosis.特立氟胺用于治疗多发性硬化症。
Cochrane Database Syst Rev. 2012 Dec 12;12:CD009882. doi: 10.1002/14651858.CD009882.pub2.
8
Discontinuing disease-modifying multiple sclerosis therapies.
Lancet Neurol. 2023 Jul;22(7):543-545. doi: 10.1016/S1474-4422(23)00200-4.

本文引用的文献

2
Patient-reported outcomes in the spotlight.患者报告的结局成为焦点。
Lancet Neurol. 2019 Nov;18(11):981. doi: 10.1016/S1474-4422(19)30357-6.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验